CliffBio
biologic

Quadracel

Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine

Loss of exclusivityJanuary 2034projected — 12-year biologic exclusivity estimate
CompanySanofi Vaccines Canada Ltd.

Drug detail

Brand nameQuadracel
Active ingredientDiphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJanuary 2022
Marketing statusRx

More from Sanofi Vaccines Canada Ltd.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Quadracel patent cliff — loss of exclusivity January 2034 | CliffBio